Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
An in situ map of copy number variations in prostate tissue reveals that purportedly cancerous genomic changes frequently occur in the healthy tissue surrounding tumors.
This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.
The University of Texas Southwestern professor’s research focused on the androgen hormones that cause male sexual differentiation and may also lead to prostate disease.
In a proof-of-concept study, researchers used dogs’ diagnoses of prostate cancer to inform a machine learning algorithm with the goal of one day detecting cancers with canine-level accuracy.
Charles Sawyers, who began his research career just as the genetic details of human oncogenes were emerging, codeveloped Gleevec, the quintessential targeted cancer therapy.